Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–52.

Article  PubMed  Google Scholar 

Rapaport F, Neelamraju Y, Baslan T, Hassane D, Gruszczynska A,Robert de Massy M, Farnoud N, Haddox S, Lee T, Medina-Martinez J, et al. Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia. 2021;35(9):2688–92.

Article  PubMed  PubMed Central  Google Scholar 

Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312–20.

Article  PubMed  CAS  Google Scholar 

Thol F, Heuser M. Treatment for Relapsed/Refractory Acute Myeloid Leukemia. Hemasphere. 2021;5(6):e572.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.

Article  PubMed  CAS  Google Scholar 

Pullarkat VA, Newman EM. BCL2 Inhibition by Venetoclax: Targeting the Achilles’ Heel of the Acute Myeloid Leukemia Stem Cell? Cancer Discov. 2016;6(10):1082–3.

Article  PubMed  CAS  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617–29.

Article  PubMed  CAS  Google Scholar 

Kater AP, Levin MD, Niemann CU. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019;381(8):788–9.

Article  PubMed  Google Scholar 

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106–17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Ann Pharmacother. 2017;51(5):410–6.

Article  PubMed  CAS  Google Scholar 

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.

Article  PubMed  Google Scholar 

Sarkis-Onofre R, Catala-Lopez F, Aromataris E, Lockwood C. How to properly use the PRISMA Statement. Syst Rev. 2021;10(1):117.

Article  PubMed  PubMed Central  Google Scholar 

Nyaga VN, Arbyn M. Correction: Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data - a tutorial. Arch Public Health. 2022;80(1):95. https://doi.org/10.1186/s13690-021-00747-5.

Article  PubMed  PubMed Central  Google Scholar 

Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141(11):1265–76.

Article  PubMed  CAS  Google Scholar 

Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, et al. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial. J Hematol Oncol. 2023;16(1):42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10.

Article  PubMed  PubMed Central  Google Scholar 

Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, et al. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022;63(9):2161–70.

Article  PubMed  CAS  Google Scholar 

Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, Popovic R, Modi DA, Joshi RH, Wolff JE, et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer. 2021;127(16):2943–53.

Article  PubMed  CAS  Google Scholar 

Jonas BA, Hou JZ, Roboz GJ, Alvares CL, Jeyakumar D, Edwards JR, Erba HP, Kelly RJ, Rollig C, Fiedler W, et al. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematol Oncol. 2023;41(4):743–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–21.

Article  PubMed  CAS  Google Scholar 

Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O’Connell MJ, Wiernik PH, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018;93(8):1074–81.

Article  PubMed  PubMed Central  Google Scholar 

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–36.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923–32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu D, Yang Y, Yin Z, Tu S, Nie D, Li Y, Huang Z, Sun Q, Huang C, Nie X, et al. Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study. Blood Cancer J. 2023;13(1):168.

Article  PubMed  PubMed Central  Google Scholar 

Tibes R, Kosiorek HE, Dueck AC, Palmer J, Sproat L, Bogenberger J, Hashmi S, Mesa R, Hogan W, Litzow MR, et al. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. Cancer. 2023;129(15):2321–30.

Article  PubMed  CAS  Google Scholar 

Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017;18(3):17.

Article  PubMed  Google Scholar